These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21572705)

  • 21. Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children.
    Pegoraro V; Urbinati D; Visser GHA; Di Renzo GC; Zipursky A; Stotler BA; Spitalnik SL
    PLoS One; 2020; 15(7):e0235807. PubMed ID: 32687543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fetal and Neonatal Alloimmune Thrombocytopenia-New Prospects for Fetal Risk Assessment of HPA-1a-Negative Pregnant Women.
    Kjeldsen-Kragh J; Bengtsson J
    Transfus Med Rev; 2020 Oct; 34(4):270-276. PubMed ID: 33039264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Red blood cell alloimmunization prevalence and hemolytic disease of the fetus and newborn in Israel: A retrospective study.
    Rahimi-Levene N; Chezar J; Yahalom V;
    Transfusion; 2020 Nov; 60(11):2684-2690. PubMed ID: 32770778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is antibody screening in Rh (D)-positive pregnant women necessary?
    Lurie S; Eliezer E; Piper I; Woliovitch I
    J Matern Fetal Neonatal Med; 2003 Dec; 14(6):404-6. PubMed ID: 15061320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rh isoimmunization in Sub-Saharan Africa indicates need for universal access to anti-RhD immunoglobulin and effective management of D-negative pregnancies.
    Osaro E; Charles AT
    Int J Womens Health; 2010 Dec; 2():429-37. PubMed ID: 21270966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility.
    Smith HM; Shirey RS; Thoman SK; Jackson JB
    Immunohematology; 2013; 29(4):127-30. PubMed ID: 24689681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Red Cell Alloimmunization to Rhesus Antigen Among Pregnant Women Attending a Tertiary Care Hospital in Oman.
    Al-Dughaishi T; Al Harrasi Y; Al-Duhli M; Al-Rubkhi I; Al-Riyami N; Al Riyami A; Pathare AV; Gowri V
    Oman Med J; 2016 Jan; 31(1):77-80. PubMed ID: 26813962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case report of haemolytic disease of the foetus and newborn caused by Alloantibody D and Jka in a Rhesus D negative Nigerian woman: Justification for the implementation of universal access to prophylaxis and evidenced-based best practices.
    Erhabor O; Azachi WB; Tosan E
    Hum Antibodies; 2020; 28(3):245-252. PubMed ID: 32417769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Positive Coomb's test in newborns; causes and clinical consequences Summary of cases diagnosed in the Blood Bank in the years 2005 to 2012].
    Kristinsdottir T; Kjartansson S; Hardardottir H; Jonsson T; Halldorsdottir AM
    Laeknabladid; 2016 Jul; 102(7-8):326-31. PubMed ID: 27531851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Guide to Terminology for Rh Immunoprophylaxis.
    Sandler SG; Queenan JT
    Obstet Gynecol; 2017 Sep; 130(3):633-635. PubMed ID: 28796682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe hemolytic disease of the fetus and newborn due to anti-E and anti-Jka.
    Mandal S; Malhotra S; Negi G; Tiwari A; Mitra S; Basu S; Singh P
    Immunohematology; 2020 Jun; 36(2):60-63. PubMed ID: 32667819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rhesus-D zygosity and hemolytic disease of fetus and newborn.
    Moghaddam M; Naghi A; Hassani F; Amini S
    Asian J Transfus Sci; 2013 Jul; 7(2):156-7. PubMed ID: 24014950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The routine use of Rh-negative reagent red cells for the identification of anti-D and the detection of non-D red cell antibodies.
    Shulman IA; Calderon C; Nelson JM; Nakayama R
    Transfusion; 1994 Aug; 34(8):666-70. PubMed ID: 8073481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe ABO hemolytic disease of fetus and newborn requiring blood exchange transfusion.
    Jain A; Malhotra S; Marwaha N; Kumar P; Sharma RR
    Asian J Transfus Sci; 2018; 12(2):176-179. PubMed ID: 30692807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation.
    Crowther CA; Middleton P; McBain RD
    Cochrane Database Syst Rev; 2013 Feb; (2):CD000020. PubMed ID: 23450526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of Rh alloimmunization.
    Fung Kee Fung K; Eason E; Crane J; Armson A; De La Ronde S; Farine D; Keenan-Lindsay L; Leduc L; Reid GJ; Aerde JV; Wilson RD; Davies G; Désilets VA; Summers A; Wyatt P; Young DC;
    J Obstet Gynaecol Can; 2003 Sep; 25(9):765-73. PubMed ID: 12970812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management.
    Slootweg YM; Lindenburg IT; Koelewijn JM; Van Kamp IL; Oepkes D; De Haas M
    Am J Obstet Gynecol; 2018 Oct; 219(4):393.e1-393.e8. PubMed ID: 30063902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Significance of alloantibodies other than anti-D hemolytic disease of the fetus and newborn (HDF/N)].
    Lenkiewicz B; Zupańska B
    Ginekol Pol; 2003 Jan; 74(1):48-54. PubMed ID: 12715437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn].
    Starcević M; Mataija M; Sović D; Dodig J; Matijević R; Kukuruzović M
    Acta Med Croatica; 2011 Mar; 65(1):49-54. PubMed ID: 21568074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemolytic disease of the fetus and newborn due to multiple alloantibodies in pregnancy.
    Gupta V; Sidhu M; Shah SN
    Asian J Transfus Sci; 2020; 14(1):83-86. PubMed ID: 33162715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.